BIO Wants Waxman/Hatch Reform Isolated From Generic Biologics

BIO hopes that jurisdictional considerations will prevent the Senate Judiciary Committee's discussion of Waxman/Hatch revisions from becoming a forum for arguments over an FDA approval process for generic versions of biological products.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet